Free Trial
NASDAQ:KIDS

OrthoPediatrics Q2 2025 Earnings Report

OrthoPediatrics logo
$21.24 -1.24 (-5.52%)
As of 04:00 PM Eastern

OrthoPediatrics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.17
Beat/Miss
N/A
One Year Ago EPS
N/A

OrthoPediatrics Revenue Results

Actual Revenue
N/A
Expected Revenue
$61.40 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

OrthoPediatrics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

OrthoPediatrics Earnings Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
OrthoPediatrics amends acquisition agreement terms
See More OrthoPediatrics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OrthoPediatrics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OrthoPediatrics and other key companies, straight to your email.

About OrthoPediatrics

OrthoPediatrics (NASDAQ:KIDS) (NASDAQ: KIDS) is a medical device company dedicated exclusively to pediatric orthopedics, developing specialized implants and instruments designed to meet the unique anatomical and physiological needs of children. Headquartered in Warsaw, Indiana—often referred to as the “Orthopedic Capital of the World”—the company focuses on addressing conditions such as fractures, deformities, and congenital disorders through innovative solutions tailored for growing patients.

The company’s product portfolio spans multiple clinical areas, including trauma and deformity, spine, sports medicine, and foot and ankle. OrthoPediatrics offers a range of small-profile plates, screws, nails and rods, as well as dedicated instrumentation and surgical navigation systems. Each offering is engineered to provide optimized fixation and correction in pediatric applications, drawing from adult implant technology but scaled down to enhance surgical precision, reduce soft tissue disruption and support healthier long-term outcomes for young patients.

Founded in 2006, OrthoPediatrics has expanded its operations through organic growth and strategic collaborations, culminating in a public listing in December 2017. The company maintains an international footprint with offices and subsidiaries across Europe, Latin America, Canada, Australia, New Zealand and select markets in Asia. Partnerships with leading pediatric orthopedic surgeons and academic centers drive its research and development efforts, while a global distributor network ensures broad access to its full product line.

Leadership at OrthoPediatrics combines deep orthopedic experience with medical device commercialization expertise. Under the direction of CEO Mike Allegrezza and a management team that includes seasoned professionals in finance, operations and clinical affairs, the company continues to invest in new product innovation, surgeon training programs and evidence-based studies. Its ongoing commitment to pediatric orthopedic care underscores a mission to improve the quality of life for children worldwide.

View OrthoPediatrics Profile

More Earnings Resources from MarketBeat